Like Novo Nordisk’s Ozempic and Wegovy, both of Eli Lilly’s tirzepatide drugs are injected on a weekly basis. Eli Lilly is studying the pill in a longer study in people who are overweight or have obesity to see if the weight loss continues. Orforglipron showed similar gastrointestinal side effects as other GLP-1 drugs, with the most common being diarrhea, nausea, indigestion, and constipation. (Injected GLP-1 drugs were in shortage until recently.) A GLP-1 pill wouldn’t need sophisticated cold-chain distribution and storage, meaning it could be sold in countries that don’t have that infrastructure.